Outcome of Board Meeting

Pfizer Limited The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274 September 7, 2026 The Corporate Relationship Dept. The Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1st Floor, P.J.Towers Exchange Plaza, 5th Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER Dear Sirs / Madam, Sub: Outcome of Board Meeting – Discontinuation of Minipress XL. Ref.: Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you the outcome of the meeting of Board of Directors of the Company held today, i.e., September 7, 2026, that commenced at 10.33 a.m. and concluded at 11.03 a.m. as under: Pfizer Limited (“the Company”) will discontinue the marketing, distribution and sale of Minipress XL with effect from September 7, 2026. This is consequent to a decision by Pfizer Inc. USA. to discontinue the manufacture of Minipress XL. In connection with the above, the Company will receive a lump sum payment of USD 13.9 Million (~Rs. 131.38 Crore) from Pfizer Inc. USA. Request you to please take the above on record. Thanking you, Yours truly, For Pfizer Limited Prajeet Nair Director – Corporate Services & Company Secretary CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in